Have a feature idea you'd love to see implemented?
Let us know!
CLNN Clene Inc
Price (delayed)
$4.8
Market cap
$38.3M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.28
Enterprise value
$46.48M
Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new
Highlights
The company's debt fell by 30% QoQ and by 28% YoY
CLNN's EPS is up by 43% year-on-year but it is down by 19% since the previous quarter
The net income is down by 18% QoQ but it is up by 11% YoY
The equity has plunged by 119% YoY
CLNN's quick ratio has plunged by 78% YoY and by 19% from the previous quarter
Key stats
What are the main financial stats of CLNN
Market
Valuations
Earnings
Shares outstanding
7.98M
Market cap
$38.3M
Enterprise value
$46.48M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
74.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
110.41
Revenue
$421,000
Gross profit
$331,000
Net income
-$36.02M
EBIT
-$31.28M
EBITDA
-$29.1M
Free cash flow
-$23.69M
Per share
Balance sheet
Liquidity
EPS
-$5.28
EPS diluted
-$5.28
Free cash flow per share
-$3.61
Book value per share
-$0.64
Revenue per share
$0.06
TBVPS
$4.81
Total assets
$31.57M
Total liabilities
$35.69M
Debt
$22.88M
Equity
-$4.13M
Working capital
-$4.13M
Debt to equity
-5.55
Current ratio
0.83
Quick ratio
0.62
Net debt/EBITDA
-0.28
Margins
Efficiency
Dividend
EBITDA margin
-6,912.4%
Gross margin
78.6%
Net margin
-8,556.8%
Operating margin
-8,163.4%
Return on assets
-85.1%
Return on equity
-1,106.3%
Return on invested capital
-126.5%
Return on capital employed
-404%
Return on sales
-7,429%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLNN stock price
How has the Clene stock price performed over time
Intraday
-3.03%
1 week
-18.51%
1 month
-3.03%
1 year
-50%
YTD
-9.6%
QTD
-9.6%
Financial performance
How have Clene's revenue and profit performed over time
Revenue
$421,000
Gross profit
$331,000
Operating income
-$34.37M
Net income
-$36.02M
Gross margin
78.6%
Net margin
-8,556.8%
The company's net margin has shrunk by 52% YoY and by 24% QoQ
The gross profit has contracted by 47% YoY and by 8% from the previous quarter
The revenue fell by 41% YoY and by 4.8% QoQ
Clene's operating margin has decreased by 39% YoY
Growth
What is Clene's growth rate over time
Valuation
What is Clene stock price valuation
P/E
N/A
P/B
N/A
P/S
74.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
110.41
CLNN's EPS is up by 43% year-on-year but it is down by 19% since the previous quarter
The equity has plunged by 119% YoY
The stock's price to sales (P/S) is 89% less than its 5-year quarterly average of 710.2 and 3.8% less than its last 4 quarters average of 77.7
The revenue fell by 41% YoY and by 4.8% QoQ
Efficiency
How efficient is Clene business performance
CLNN's return on sales is down by 48% year-on-year and by 29% since the previous quarter
Clene's return on invested capital has decreased by 46% QoQ and by 40% YoY
The ROA has contracted by 38% from the previous quarter and by 12% YoY
Dividends
What is CLNN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLNN.
Financial health
How did Clene financials performed over time
The total assets is 12% smaller than the total liabilities
CLNN's quick ratio has plunged by 78% YoY and by 19% from the previous quarter
The company's current ratio has shrunk by 73% YoY and by 16% QoQ
The equity has plunged by 119% YoY
Clene's debt to equity has surged by 91% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.